- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05572515
Un estudio que compara la monoterapia con teclistamab versus pomalidomida, bortezomib, dexametasona (PVd) o carfilzomib, dexametasona (Kd) en participantes con mieloma múltiple en recaída o refractario (MajesTEC-9)
Un estudio aleatorizado de fase 3 que compara la monoterapia con teclistamab versus pomalidomida, bortezomib, dexametasona (PVd) o carfilzomib, dexametasona (Kd) en participantes con mieloma múltiple en recaída o refractario que han recibido de 1 a 3 líneas de terapia previas, incluido un anticuerpo monoclonal anti-CD38 y Lenalidomida
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Acceso ampliado
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Cottbus, Alemania, 03048
- Medizinische Universitat Lausitz Carl Thiem
-
Dresden, Alemania, 01307
- Universitatsklinikum Carl Gustav Carus Dresden
-
Greifswald, Alemania, 17475
- Universitätsmedizin Greifswald
-
Hamburg, Alemania, 22763
- Asklepios Klinik Altona
-
Heidelberg, Alemania, 69120
- Universitaetsklinikum Heidelberg
-
Marburg, Alemania, 35043
- Universitaetsklinikum Giessen und Marburg GmbH
-
Tübingen, Alemania, 72076
- Universitatsklinikum Tubingen
-
Ulm, Alemania, 89070
- Universitatsklinikum Ulm
-
Zwickau, Alemania, 08060
- Heinrich-Braun-Klinikum gGmbH
-
-
-
-
-
Blacktown, Australia, 2148
- Blacktown Hospital
-
Fitzroy, Australia, 3065
- St Vincents Hospital Melbourne
-
Melbourne, Australia, 3128
- Box Hill Hospital
-
Murdoch, Australia, 6150
- Fiona Stanley Hospital
-
Nedlands, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Salzburg, Austria, 5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna, Austria, A-1090
- Medical University Vienna MUV
-
-
-
-
-
Brasília, Brasil, 70390-140
- Hospitais Integradaos da Gavea S/A - DF Star
-
Caxias do Sul, Brasil, 95070 560
- Fundacao Universidade de Caxias do Sul
-
Curitiba, Brasil, 81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Joinville, Brasil, 89201-260
- Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
-
Natal, Brasil, 59062 000
- Liga Norte Riograndense Contra O Cancer
-
Niterói, Brasil, 24020-073
- Complexo Hospitalar de Niteroi
-
Rio de Janeiro, Brasil, 22775-001
- Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
-
Salvador, Brasil, 41253-190
- IDOR - Regional Bahia
-
São José do Rio Preto, Brasil, 15090-000
- Funfarme Sjrp
-
São Paulo, Brasil, 05652-900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasil, 01323-001
- Hospital Alemao Oswaldo Cruz
-
São Paulo, Brasil, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasil, 01308-901
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
São Paulo, Brasil, 04537 081
- Clinica Medica Sao Germano LTDA
-
São Paulo, Brasil, 01401 002
- IDOR - Regional Sao Paulo
-
São Paulo, Brasil, 01321-001
- Real e Benemérita Associação Portuguesa de Beneficência
-
-
-
-
-
Brasschaat, Bélgica, 2930
- Algemeen Ziekenhuis Klina
-
Haine-St-Paul, Bélgica, 7100
- Jolimont
-
Kortrijk, Bélgica, 8500
- Az Groeninge
-
Leuven, Bélgica, 3000
- Universitair Ziekenhuis Gasthuisberg
-
Liège, Bélgica, 4000
- CHR de la Citadelle
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
-
New Brunswick
-
Saint John, New Brunswick, Canadá, E2L 4L2
- Saint John Regional Hospital
-
-
Ontario
-
Brampton, Ontario, Canadá, L6R 3J7
- Brampton Civic Hospital
-
Oshawa, Ontario, Canadá, L1G2B9
- Lakeridge Health Oshawa
-
-
Quebec
-
Montreal, Quebec, Canadá, H1T 2M4
- CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
-
-
-
-
-
Brno, Chequia, 625 00
- Fakultni nemocnice Brno
-
Olomouc, Chequia, 779 00
- Fakultni nemocnice Olomouc
-
Ostrava - Poruba, Chequia, 708 52
- Fakultni Nemocnice Ostrava
-
Prague, Chequia, 128 08
- Vseobecna fakultni nemocnice v Praze
-
-
-
-
-
Aalborg, Dinamarca, 9000
- Aalborg University Hospital
-
Aarhus, Dinamarca, 8200
- Aarhus University Hospital
-
Copenhagen, Dinamarca, DK-2100
- Rigshospitalet
-
Herning, Dinamarca, 7400
- Regionshospitalet Godstrup
-
Odense C, Dinamarca, 5000
- Odense Universitetshospital
-
Vejle, Dinamarca, 7100
- Vejle Sygehus
-
-
-
-
-
Badalona, España, 08916
- Hosp. Univ. Germans Trias I Pujol
-
Jerez de la Frontera, España, 11407
- Hosp. de Jerez de La Frontera
-
L'Hospitalet de Llobregat, España, 08908
- Institut Catala d Oncologia L Hospitalet
-
León, España, 24008
- Hosp. de Leon
-
Madrid, España, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, España, 28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid, España, 28031
- Hosp. Univ. Infanta Leonor
-
Murcia, España, 30008
- Hosp. Gral. Univ. J.M. Morales Meseguer
-
Oviedo, España, 33011
- Hospital Universitario Central de Asturias
-
Palma de Mallorca, España, 07198
- Hosp. Son Llatzer
-
Pontevedra, España, 36071
- Hosp. Montecelo
-
Pozuelo de Alarcón, España, 28223
- Hosp. Quiron Madrid Pozuelo
-
Valencia, España, 46026
- Hospital Universitari i Politecnic La Fe
-
-
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Oncology and Hematology LLC
-
-
Arizona
-
Gilbert, Arizona, Estados Unidos, 85234
- Banner MD Anderson Cancer Center
-
-
California
-
Berkeley, California, Estados Unidos, 94704
- Alta Bates Comprehensive Cancer Center
-
Long Beach, California, Estados Unidos, 90806
- MemorialCare Long Beach Medical Center
-
Orange, California, Estados Unidos, 92868
- University of California Irvine
-
Whittier, California, Estados Unidos, 90602
- PIH Health Hospital
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80218
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
Farmington, Connecticut, Estados Unidos, 06030
- University of Connecticut
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Sylvester Cancer Center
-
Orlando, Florida, Estados Unidos, 32806
- Orlando Health Cancer Institute
-
Weston, Florida, Estados Unidos, 33331
- Cleveland Clinic Florida
-
-
Iowa
-
Waukee, Iowa, Estados Unidos, 50263
- Mission Cancer Blood
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- East Jefferson General Hospital Bone Marrow Transport Clinic
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20889
- Walter Reed National Military Medical Center
-
Silver Spring, Maryland, Estados Unidos, 20904
- Maryland Oncology Hematology P A
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02118
- Boston University Medical Center
-
-
Missouri
-
Chesterfield, Missouri, Estados Unidos, 63017
- Saint Lukes Hospital Saint Lukes Cancer Specialists
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Cooper Health System MD Anderson Cancer Center at Cooper
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Durham VAMC
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Estados Unidos, 17601
- Penn Medicine Lancaster General Health
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Tennessee Oncology
-
-
Texas
-
Fort Sam Houston, Texas, Estados Unidos, 78234
- Brooke Army Medical Center
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine
-
Houston, Texas, Estados Unidos, 77030
- Michael E DeBakey VA Medical Center
-
Houston, Texas, Estados Unidos, 77054
- Harris Health Smith Clinic
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84106
- Utah Cancer Specialists
-
-
Virginia
-
Fort Belvoir, Virginia, Estados Unidos, 22060
- Alexander T. Augusta Military Medical Center
-
Norfolk, Virginia, Estados Unidos, 23502
- Virginia Oncology Associates
-
-
Washington
-
Tacoma, Washington, Estados Unidos, 98405
- NorthWest Medical Specialties, PLLC
-
-
-
-
-
Amiens, Francia, 80000
- CHU Amiens - Hopital Sud
-
Caen, Francia, 14000
- Hôpital Côte de Nacre
-
Grenoble, Francia, 38700
- CHU Grenoble
-
Le Mans, Francia, 72037
- Centre Hospitalier du Mans
-
Lille, Francia, 59020
- Hopital Saint Vincent de Paul
-
Montpellier, Francia, 34295 cede
- CHU de Montpellier Hopital Saint Eloi
-
Nantes, Francia, 44000
- CHU Nantes
-
Paris, Francia, 75743
- Hopital Necker Enfants Malades
-
Paris, Francia, 75012
- Hopital Saint-Antoine
-
Paris, Francia, 75013
- Hopital de la Pitie Salpetriere
-
Toulouse, Francia, 31100
- Institut Universitaire du Cancer Toulouse Oncopole
-
Vandœuvre-lès-Nancy, Francia, 54500
- CHU de Nancy - Hopital de Brabois
-
-
-
-
-
Athens Attica, Grecia, 115 28
- Alexandra General Hospital of Athens
-
Pátrai, Grecia, 263 35
- Agios Andreas General Hospital of Patra
-
Thessaloniki, Grecia, 570 10
- G Papanikolaou Hospital of Thessaloniki
-
-
-
-
-
Gūrgaon, India, 122002
- Fortis Memorial Research Institute
-
Jaipur, India, 302017
- Bhagwan Mahaveer Cancer Hospital & Research Centre
-
Pune, India, 411004
- Deenanath Mangeshkar Hospital and Research Centre
-
-
-
-
-
Hadera, Israel, 3810101
- Hillel Yaffe Medical Center
-
Haifa, Israel, 31048
- Bnai Zion Medical Center
-
Haifa, Israel, 3436212
- Carmel Medical Center
-
Petah Tikva, Israel, 49100
- Rabin Medical Center
-
Ramat Gan, Israel, 52621
- Sheba Medical Center
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Bologna, Italia, 40138
- A O U Sant Orsola Malpighi
-
Milan, Italia, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Palermo, Italia, 90127
- Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
-
Pisa, Italia, 56126
- Ospedale Santa Chiara AO Universitaria Pisana
-
Reggio Emilia, Italia, 42123
- Arcispedale Santa Maria Nuova - IRCCS
-
Roma, Italia, 00128
- Campus Bio Medico di Roma
-
Siena, Italia, 53100
- A O Universitaria Senese Ospedale Santa Maria alle Scotte
-
Turin, Italia, 10126
- A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
-
Udine, Italia, 33100
- ASUI Santa Maria della Misericordia di Udine
-
Varese, Italia, 21100
- Ospedale di Circolo e Fondazione Macchi
-
-
-
-
-
Bunkyō City, Japón, 113 8519
- Institute of Science Tokyo Hospital
-
Chiba, Japón, 260-8717
- Chiba Cancer Center
-
Gifu, Japón, 503-8502
- Ogaki Municipal Hospital
-
Gunma, Japón, 377-0280
- National Hospital Organization Shibukawa Medical Center
-
Hirakata, Japón, 573 1191
- Kansai Medical University Hospital
-
Hitachi, Japón, 317-0077
- Hitachi General Hospital
-
Iruma-gun, Japón, 350-0495
- Saitama Medical University Hospital
-
Kamogawa, Japón, 296-8602
- Kameda Medical Center
-
Kashiwa, Japón, 277 8577
- National Cancer Center Hospital East
-
Kurashiki, Japón, 710-8602
- Kurashiki Central Hospital
-
Matsuyama, Japón, 790-8524
- Matsuyama Red Cross Hospital
-
Nagakute, Japón, 480-1195
- Aichi Medical University Hospital
-
Nagasaki, Japón, 852-8511
- JRC Nagasaki Genbaku Hospital
-
Niigata, Japón, 951 8520
- Niigata University Medical And Dental Hospital
-
Okayama, Japón, 701-1192
- National Hospital Organization Okayama Medical Center
-
Osaka, Japón, 545 8586
- Osaka Metropolitan University Hospital
-
Sapporo, Japón, 060-8648
- Hokkaido University Hospital
-
Tokyo, Japón, 113-0033
- Juntendo University Hospital
-
Tokyo, Japón, 135 8550
- The Cancer Institute Hospital of JFCR
-
Yamagata, Japón, 990 2331
- Yamagata University Hospital
-
Yamanashi, Japón, 400-8506
- Yamanashi Prefectural Central Hospital
-
-
-
-
-
George Town, Malasia, 10450
- Hospital Pulau Pinang
-
Kota Kinabalu, Malasia, 88200
- Hospital Queen Elizabeth
-
Kuala Lumpur, Malasia, 59100
- University Malaya Medical Centre
-
Subang Jaya, Malasia, 47500
- Subang Jaya Medical Centre
-
-
-
-
-
Amersfoort, Países Bajos, 3813 TZ
- Meander Medisch Centrum
-
Amsterdam, Países Bajos, 1081 HV
- VUMC Amsterdam
-
Groningen, Países Bajos, 9700 RB
- Universitair Medisch Centrum Groningen
-
Utrecht, Países Bajos, 3584 CX
- UMC Utrecht
-
-
-
-
-
Gdansk, Polonia, 80 214
- Uniwersyteckie Centrum Kliniczne
-
Katowice, Polonia, 40 519
- Pratia Onkologia Katowice
-
Kielce, Polonia, 25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Lublin, Polonia, 20-081
- Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
-
-
-
-
-
Beijing, Porcelana, 100020
- Beijing Chaoyang Hospital
-
Beijing, Porcelana, 102208
- BeiJing JiShuiTan Hospital
-
Changchun, Porcelana, 130021
- The First Bethune Hospital of Jilin University
-
Changsha, Porcelana, 410013
- The Third Xiangya Hospital, Central South University
-
Chengdu, Porcelana, 610032
- Sichuan Provincial Peoples Hospital
-
Chongqing, Porcelana, 400030
- Chongqing University Cancer Hospital
-
Fuzhou, Porcelana, 350001
- Fujian Meidical University Union Hospital
-
Guangzhou, Porcelana, 511363
- Sun Yat -Sen University Cancer Center
-
Hangzhou, Porcelana, 310003
- First affiliated Hospital of Zhejiang University
-
Hangzhou, Porcelana, 310003
- First affiliated Hospital of Zhejiang University 1
-
Harbin, Porcelana, 150000
- Harbin medical university cancer hospital
-
Nanchang, Porcelana, 330006
- The First Affiliated Hospital of NanChang University
-
Nanjing, Porcelana, 210008
- Nanjing Drum Tower Hospital
-
Nanning, Porcelana, 530021
- First Affiliated Hospital of Guangxi Medical University
-
Shanghai, Porcelana, 200434
- Shanghai Fourth People s Hospital
-
Shenyang, Porcelana, 110055
- Shengjing Hospital Of China Medical University
-
Shenzhen, Porcelana, 518025
- Shenzhen 2nd People's Hospital
-
Tianjin, Porcelana, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Tianjin, Porcelana, 301617
- Institute of Hematology and Blood Diseases Hospital
-
Wenzhou, Porcelana, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Porcelana, 430023
- Wuhan Union Hospital
-
Wuxi, Porcelana, 214023
- Wuxi People s Hospital
-
Xi'an, Porcelana, 710004
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Zhengzhou, Porcelana, 450008
- Henan Cancer Hospital
-
-
-
-
-
Almada, Portugal, 2805-267
- Uls Almada Seixal - Hosp. Garcia de Orta
-
Braga, Portugal, 4710-243
- Uls Braga - Hosp. Braga
-
Lisbon, Portugal, 1400-038
- Champalimaud Foundation Champalimaud Centre
-
Porto, Portugal, 4200072
- Instituto Portugues de Oncologia
-
Vila Nova de Gaia, Portugal, 4434-502
- Uls Gaia Espinho
-
-
-
-
-
Aberdeen, Reino Unido, AB25 2ZN
- Aberdeen Royal Infirmary
-
Birmingham, Reino Unido, B15 2GW
- University Hospitals Birmingham NHS Foundation Trust
-
Colchester, Reino Unido, CO4 5JL
- Colchester Hospital University NHS
-
Liverpool, Reino Unido, L7 8YA
- The Clatterbridge Cancer Centre
-
London, Reino Unido, SW17 0QT
- St Georges Hospital
-
London, Reino Unido, SW10 9NH
- Chelsea And Westminster Hospital
-
Middlesbrough, Reino Unido, Ts4 3Bw
- James Cook University Hospital
-
Norwich, Reino Unido, NR4 7UY
- Norfolk and Norwich University Hospital
-
Staffordshire, Reino Unido, ST4 6QG
- Royal Stoke University Hospital
-
-
-
-
-
Falun, Suecia, 791 82
- Falu Lasarett Medicinkliniken Falun
-
Helsingborg, Suecia, 25287
- Helsingborgs lasarett
-
Uppsala, Suecia, 751 85
- Akademiska Sjukhuset
-
-
-
-
-
Ankara, Turquía (Türkiye), 06200
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Turquía (Türkiye), 06680
- Liv Hospital Ankara
-
Ankara, Turquía (Türkiye), 06620
- Ankara University Medical Faculty
-
Ankara, Turquía (Türkiye), 06010
- Ankara Gulhane Training and Research Hospital
-
Antalya, Turquía (Türkiye), 07100
- Antalya Training And Research Hospital
-
Denizli, Turquía (Türkiye), 20070
- Pamukkale University Medical Faculty
-
Istanbul, Turquía (Türkiye), 34214
- Medipol Mega Universite Hastanesi
-
Samsun, Turquía (Türkiye), 55280
- Ondokuz Mayis University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) Measurable disease at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level >=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line
- Documented evidence of progressive disease or failure to achieve a response to last line of therapy based on investigator's determination of response by International myeloma working group (IMWG) criteria
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
- Must be willing and able to adhere to the lifestyle restrictions specified in this protocol
Exclusion Criteria:
- Received any prior B cell maturation antigen (BCMA)-directed therapy
- A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (>=) 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (>)159 millimeters of mercury (mmHg) or diastolic blood pressure >99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade >=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event [AE] related to carfilzomib)
- Received a maximum cumulative dose of corticosteroids of >=140 mg of prednisone or equivalent within 14 days prior to randomization
- Received a live, attenuated vaccine within 4 weeks before randomization
- Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma
- Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Teclistamab
Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2. Participants who are still receiving the treatment and benefiting from it may enter the long-term extension (LTE) and drug access (DA)-LTE Phases to continue their current treatment until end of the study. |
Teclistamab will be administered subcutaneously.
Otros nombres:
|
|
Experimental: Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)
Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study. Participants who are still receiving the treatment and benefiting from it may enter the LTE and DA-LTE Phases to continue their current treatment until end of the study. |
Pomalidomide will be administered orally. Carfilzomib will be administered intravenously. Bortezomib will be administered subcutaneously. Dexamethasone will be administered orally in PVd and intravenously or orally in Kd. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1: Progression-free Survival (PFS)
Periodo de tiempo: Up to 9 years
|
PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International myeloma working group (IMWG) 2016 response criteria, or death due to any cause, whichever occurs first. |
Up to 9 years
|
|
Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity
Periodo de tiempo: Up to 9 years
|
Severity for CRS will be graded as follows: Grade 1: Fever (Temperature greater than or equal to [>=] 38°C); Grade 2: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring low-flow nasal cannula or blow-by; Grade 3: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask; Grade 4: Fever (Temperature >=38°C) with either: hypotension requiring multiple vasopressors (excluding vasopressin), and/or hypoxia requiring positive pressure and Grade 5: Death. |
Up to 9 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1 and 2: Overall Response (Partial Response [PR] or Better)
Periodo de tiempo: Up to 9 years
|
Overall response (PR or better) is defined as participants who have a PR or better prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria. |
Up to 9 years
|
|
Part 1 and 2: Very Good Partial Response (VGPR) or Better Response
Periodo de tiempo: Up to 9 years
|
VGPR or better (Stringent Complete Response [sCR]+Complete Response [CR]+VGPR) is defined as participants who achieve a VGPR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria. |
Up to 9 years
|
|
Part 1 and 2: Complete Response (CR) or Better Response
Periodo de tiempo: Up to 9 years
|
CR or better response is defined as participants who achieve a CR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria. |
Up to 9 years
|
|
Part 1: Duration of Response (DOR)
Periodo de tiempo: Up to 9 years
|
DOR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG 2016 response criteria or death due to any cause, whichever occurs first. |
Up to 9 years
|
|
Part 1: Time to Next Treatment (TTNT)
Periodo de tiempo: Up to 9 years
|
TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment. |
Up to 9 years
|
|
Part 1: Progression-free Survival on Next-line Therapy (PFS2)
Periodo de tiempo: Up to 9 years
|
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first. |
Up to 9 years
|
|
Part 1: Overall Survival (OS)
Periodo de tiempo: Up to 9 years
|
OS is defined as the time from the date of randomization to the date of the participant's death due to any cause. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Adverse Events (AEs) by Severity
Periodo de tiempo: Up to 9 years
|
Number of participants with AEs by Severity will be reported. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Serious Adverse Events (SAEs) by Severity
Periodo de tiempo: Up to 9 years
|
Number of participants with SAEs by Severity will be reported. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Abnormal Laboratory Results
Periodo de tiempo: Up to 9 years
|
Number of participants with abnormal laboratory results (such as hematology and chemistry) will be reported. |
Up to 9 years
|
|
Part 1 and 2: Serum Concentrations of Teclistamab
Periodo de tiempo: Up to 9 years
|
Serum concentrations of teclistamab will be reported. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab
Periodo de tiempo: Up to 9 years
|
Number of participants with ADAs to teclistamab will be reported. |
Up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
Periodo de tiempo: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by EORTC QLQ-C30 score version 3 will be reported. The EORTC- QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. |
Baseline up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
Periodo de tiempo: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by MySIm-Q will be reported. The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale. |
Baseline up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Periodo de tiempo: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by PRO-CTCAE will be reported. The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact. |
Baseline up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Periodo de tiempo: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by EQ-5D-5L will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Baseline up to 9 years
|
|
Part 1: Time to Worsening in Symptoms, Functioning, and Overall HRQoL
Periodo de tiempo: Up to 9 years
|
Time to worsening in symptoms, functioning, and overall HRQoL will be measured as the interval from the date of randomization to the start date of meaningful change. |
Up to 9 years
|
|
Part 1: PFS in Participants in High-risk Molecular Features
Periodo de tiempo: Up to 9 years
|
PFS in participants in high-risk molecular features will be reported. PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the IMWG 2016 response criteria, or death due to any cause, whichever occurs first. |
Up to 9 years
|
|
Part 1: Depth of Response in Participants in High-risk Molecular Features
Periodo de tiempo: Up to 9 years
|
Depth of response in participants in high-risk molecular features will be reported. |
Up to 9 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Enfermedades hemic y linfáticas
- Mieloma múltiple
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos policíclicos
- Químicos inorgánicos
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Esteroides, fluorado
- Esparrazadienetrioles
- Ácidos borónicos
- Ácidos, no carboxílicos
- Ácidos
- Compuestos de boro
- Pirazinas
- Bortezomib
- Dexametasona
- carfilzomib
- pomalidomida
Otros números de identificación del estudio
- CR109244
- 64007957MMY3006 (Otro identificador: Janssen Research & Development, LLC)
- 2022-000928-37 (Número EudraCT)
- 2023-503444-13-00 (Identificador de registro: EUCT number)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .